iSpecimen Inc. Reports Board and Executive Changes

Ticker: ISPC · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1558569

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

TL;DR

iSpecimen board shakeup and comp changes effective July 5th.

AI Summary

On July 5, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and directors, alongside the election of new directors and adjustments to compensatory arrangements for key personnel. These changes are effective as of July 5, 2024.

Why It Matters

Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and stability.

Key Players & Entities

FAQ

What specific roles have seen departures or appointments?

The filing indicates the departure of certain officers and directors, and the election of new directors, but does not specify the exact roles affected in this summary.

When were these changes effective?

The changes reported in the 8-K were effective as of July 5, 2024.

What is the primary reason for this 8-K filing?

This 8-K filing is primarily to report the departure of directors or certain officers, the election of directors, and changes in compensatory arrangements of certain officers.

Where is iSpecimen Inc. headquartered?

iSpecimen Inc.'s principal executive offices are located at 450 Bedford Street, Suite 1010, Lexington, MA 02420.

What is the company's fiscal year end?

The company's fiscal year ends on December 31st.

Filing Stats: 400 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2024-07-08 17:00:15

Key Financial Figures

Filing Documents

02 Departure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 5, 2024, iSpecimen Inc. (the "Company") received written notice from Benjamin Bielak that he will be resigning as Chief Information Officer and Secretary of the Company, effective July 15, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 8, 2024 iSPECIMEN INC. By: /s/ Tracy Curley Name: Tracy Curley Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing